While no conclusion can be drawn from a single case, it is tempting to think that combination therapy between TKIs and anti-PD-L1 antibodies would be beneficial for CML patients. The gene discussed is CD274; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.